Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sodium-glucose cotransporter 1/2 inhibition and risk of neurodegenerative disorders: A Mendelian randomization study.

Brain and behavior - 1 Jul 2024

Liu Jinxin, Shi Xinxiu, Shao Yankun

Abstract excerpt

INTRODUCTION: This study aims to evaluate the effects of sodium-glucose cotransporter 1 inhibitors (SGLT1i) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) on neurodegenerative disorders and to investigate the role of hemoglobin A1c (HbA1c) levels. METHODS: Utilizing drug target Mendelian randomization, we employed single nucleotide polymorphisms (SNPs) proximal to the SLC5A1 and SLC5A2 genes to analyze...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease
Share to Amyotrophic Lateral Sclerosis
Share to Diabetes Mellitus, Type 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glycated Hemoglobin

Share to Mendelian Randomization Analysis

Share to Multiple Sclerosis

Share to Neurodegenerative Diseases

Share to Parkinson Disease

Source

Open in PubMed Open full text

Identifiers

PMID: 39010704
DOI: 10.1002/brb3.3624
PMCID: PMC11250420

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sodium-glucose cotransporter 1/2 inhibition and risk of neurodegenerative disorders: A Mendelian randomization study.PMID 39010704Read ↗

Two Birds With One Stone: The Protective Role of the Antidiabetic Drug Sodium-Glucose Cotransporter-2 Inhibitor in Neurodegenerative Diseases.Semantic proximity Read ↗

SGLT2 inhibition, circulating biomarkers, and Alzheimer's disease: A Mendelian randomization study.Semantic proximity Read ↗

Genetic Variation in Targets of Antidiabetic Drugs and Alzheimer Disease Risk: A Mendelian Randomization Study.Semantic proximity Read ↗

Association of SGLT-2 Inhibitors with Thyroid Dysfunction: A Drug-Target Mendelian Randomization StudySemantic proximity Read ↗

Inhibition of sodium-glucose cotransporter-2 and liver-related complications in individuals with diabetes: a Mendelian randomization and population-based cohort study.Semantic proximity Read ↗

The Effect of SGLT2 Inhibition on Brain-related Phenotypes and Aging: A Drug Target Mendelian Randomization StudySemantic proximity Read ↗

Glycemic traits and Alzheimer's disease: a Mendelian randomization study.Semantic proximity Read ↗

Pharmacological targets of SGLT2 inhibitors on IgA nephropathy and membranous nephropathy: a mendelian randomization studySemantic proximity Read ↗

SGLT1 and SGLT2 inhibition, circulating metabolites, and cerebral small vessel disease: a mediation Mendelian Randomization study.Semantic proximity Read ↗

Mendelian randomization study of sodium-glucose cotransporter 2 inhibitors in cardiac and renal diseases.Semantic proximity Read ↗

Mendelian randomization revealing the protective effect of sodium-glucose cotransporter 2 inhibition on prostate cancer with verified evidence from electronic healthcare and biological dataSemantic proximity Read ↗

Metformin Shows Greater Potential Than Semaglutide in Reducing Alzheimer’s Risk in Diabetes Type II via Dual Actions: Tackling Disease Pathways and Environmental Herpesvirus TriggersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.